BullFrog AI has entered into exclusive, worldwide agreements with two major US medical institutions for our first two therapeutic leads. Our most advanced clinical candidate is a repositioned small molecule therapeutic uniquely formulated for maximum utility against various cancers. The lead indication for this small molecule is glioblastoma, with subsequent programs anticipated for thyroid cancer, pancreatic cancer, and other undisclosed indications. Our second drug candidate is a nucleic acid therapeutic for several interrelated liver diseases including cancer, obesity, non-alcoholic steatohepatitis (NASH), and non-alcoholic fatty liver disease (NAFLD).
Our bfLEAP ™ AI/Unsupervised machine-learning platform identifies relationships and correlations from complex data structures to:
Discover novel drug targets
Find niche patient populations where a drug candidate is likely to be more effective
Identify combinations of drugs likely to provide synergistic effects
As many new medicines are developed for patients, many are still left undiscovered. The bfLEAP™ platform offers the potential to discover new mechanisms within the clinical data set, that would benefit subgroups of patients. By revitalizing these existing medicines, more therapies become available to help more patients live a better life.
For drug candidates in clinical trials, our bfLEAP™ platform analyzes such clinical trial data sets to predict which patients will respond to a particular therapy in development, thereby tailoring inclusion/exclusion criteria and enhancing primary study outcome success.